Athira Pharma (NASDAQ:LONA – Get Free Report) announced its earnings results on Monday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.27), Zacks reports.
Athira Pharma Price Performance
Shares of NASDAQ:LONA traded down $0.24 during trading on Monday, reaching $3.23. The company had a trading volume of 58,395 shares, compared to its average volume of 94,635. The firm has a market capitalization of $30.34 million, a price-to-earnings ratio of -0.77 and a beta of 1.90. The stock’s fifty day moving average price is $5.34 and its 200 day moving average price is $7.53. Athira Pharma has a fifty-two week low of $2.21 and a fifty-two week high of $14.21.
Analysts Set New Price Targets
LONA has been the subject of a number of recent research reports. Citizens Jmp decreased their price target on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research note on Monday, August 17th. Wall Street Zen upgraded shares of Athira Pharma to a “hold” rating in a research note on Saturday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Wednesday, November 4th. Finally, Mizuho reduced their target price on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, August 19th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.33.
Get Our Latest Research Report on LONA
Athira Pharma Company Profile
Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.
Read More
- Five stocks we like better than Athira Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
